<DOC>
	<DOCNO>NCT00804570</DOCNO>
	<brief_summary>The Primary objective study test whether LY2196044 reduce number heavy drinking day per month people alcohol dependence . Each subject undergo screen assessment period ( include medication washout ) prior randomization 16 week double blind treatment period .</brief_summary>
	<brief_title>A Study Treatment Alcohol Dependence</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Have Alcohol Dependence . Subjects must manifest least follow 3 requirement diagnosis Alcohol Dependence : 1 . Be tolerant , define either follow : 1 . A need markedly increase amount alcohol achieve intoxication desire effect . 2 . Markedly diminished effect continue use amount alcohol . 2 . Consume alcohol , often large amount longer period intend . 3 . Have persistent desire unsuccessful effort ( ) reduce control alcohol use . Drink average 14 drink ( woman ) 21 drink ( men ) per week least 2 heavy drinking day per week ( ≥4 drinks/day woman ≥5 drinks/day men ) consecutive 30 day period prior Screening maintain Randomization . Endorse abstinence reduction drinking . Female subject childbearing potential must negative urine pregnancy test agree use reliable method birth control study 2 month follow last dose study drug . Have experience acute alcohol withdrawal syndrome within past 6 month currently significant risk suffer acute alcohol withdrawal syndrome . Have history serious head injury , intracranial neoplasm hemorrhage , prior seizure ( remote history childhood febrile seizure ) , condition would place subject increase risk seizure . Have ever take anticonvulsant seizure control . Are diagnosed substance dependence abuse ( alcohol , cannabis , nicotine , caffeine ) within 6 month prior Screening . Are receive intensive behavioral psychological therapy , deliver license certified alcohol treatment specialist , alcohol dependence . Meet criterion lifetime diagnosis Schizophrenia , Schizoaffective Disorder , Bipolar I Disorder , psychoses . Have sign symptom active illness within past 6 month Screening diagnosis Major Depressive Disorder ( MDD ) Anxiety Disorder , Cognitive Disorder diagnose clinical assessment . Subjects diagnose MDD distant past , recent diagnosis active Major Depressive Episode , eligible . Are actively suicidal , opinion investigator . Have take opiate opioid analgesic ( example , codeine , hydrocodone ) opiate receptor antagonist ( example , naltrexone ) within 14 day prior Screening . Are currently take medication exclude protocol . Note : Subjects discontinue/washout excluded medication prior Randomization exclude participation . Have evidence significant active cardiac , respiratory , renal , gastrointestinal , hematologic disease . Have acute active hepatitis hepatic inflammation . Have history cirrhosis laboratory evidence significant hepatocellular injury . Have plasma level sodium , potassium , calcium , magnesium , phosphorous fall outside establish reference range central laboratory analytes [ , low limit normal ( LLN ) upper limit normal ( ULN ) ] unless correct prior randomization . Have electrocardiogram ( ECG ) abnormality obtain Screening clinically significant regard subject 's participation study . Are woman either pregnant breast feeding . Have receive treatment within last 30 day drug receive regulatory approval indication time study entry . Have previously complete withdrawn study study investigate LY2196044 . Are unable , unreliable , and/or unwilling provide inform consent , make available duration study abide study procedure restriction .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>